

RECEIVED

FEB 22 2002

Sheet 1 of 2  
TECH CENTER 1600/2900

FORM 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1142 MIS:ac	SERIAL NO. <del>08/042,883</del> 08/042,883
	APPLICANT Benjamin Rovinski et al.	
	FILING DATE April 27, 2001	GROUP <del>1632</del> 1636

U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
QW	WO 99/31250	Jun. 24, 1999	PCT			YES	NO
	WO 91/05864	May 2, 1991	PCT				
	WO 00/50604	Aug. 8, 2000	PCT				
	WO 98/40501	Sept. 17, 1998	PCT				
QW	WO 01/82962	Nov. 8, 2001	PCT				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*	1. UNAIDS. WHO AIDS epidemic update: December 1999. Geneva: World Health Organisation; 1999.
*	2. Heyward et al 1998. HIV vaccine development and evaluation: realistic expectations. AIDS Res Hum Retrivir 14:S205-S201.
*	3. Haigwood NL and Zolla-Pazner S. 1998. Humoral immunity to HIV, SIV and SHIV. AIDS 12: S121-S132.
*	4. Johnson et al. 1998. Cellular immune responses to HIV-1. AIDS 12: S113-S120.
*	5. Keefer, M. et al. 1996. AIDS Res Hum Retroviruses. 12:683-693.
*	6. Cox W. et al 1993. Virology 198:845-850.
*	7. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz Jr, Sinangil F, Fast PE. 1996. Ann Intern Med Aug 15;125(4):270-279.
*	8. Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, Gorse GJ. 1997. J Immunol 197 Apr 1;158(7):3511-3520.
*	9. Fang ZY et al. 1999. J Infect Dis. 180(4):1122-1132.

EXAMINER: <i>Long Nguyen</i>	DATE CONSIDERED: 11/24/04
------------------------------	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

\* Will follow shortly.



RECEIVED

FEB 22 2002  
Sheet 2 of 2

TECH CENTER 1800/2900

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1038-1142 MIS:ac		SERIAL NO. <del>06/842,883</del> 05/842,883	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Benjamin Rovinski et al.			
				FILING DATE April 27, 2001		GROUP <del>1632</del> 1636	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	*	10. Rovinski B et al. 1995. AIDS Res Hum Retroviruses. 11:1187-1195.					
	*	11. Arp J. et al. 1999. Viral Immunology 12(4):281-296.					
	*	12. Zolka-Pazner et al. J. Virology, Vol. 72:1052-1059, 1998.					
	*	13. Karin M and Richards RJ. Human metallothionein genes -- primary structure of the metallothionein-II gene and a related processed gene. Nature 1982;299:797-802.					
QN		14. Sambrook J et al. Molecular Cloning A Laboratory Manual, Second Ed.: Cold Spring Harbour Laboratory Press. 1989.					
QN		15. Haynes JR. et al. Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Hum Retroviruses 1991; 7:17-27.					
	*	16. Persson R, et al. Modifications of HIV-1 Retrovirus-like Particles to Enhance Safety and Immunogenicity. Biologicals 1998, 26(4); 255-265.					
	*	17. Southern PJ and Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Molec Appl Genet 1982;1: 327-341					
	*	18. Graham, B.S. et al. 1993, J. Infection Des. 167:533-537.					
		19. Tartaglia, J. et al., 1992, Virology, 188: 219-232					
	*	20. Piccini, A. et al., 1987, Methods in Enzymology 153: 545-563					
QN		21. Caver T. E. et al "A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, Vol. 17, no. 11-12, 1999-03, pp. 1567-1572, XP004158286					
QN		22. Evans, T.G. et al.: " A Canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers." J. Infect. Diseases, vol. 180, 1999, pp. 290-298, XP002185651.					
EXAMINER:				DATE CONSIDERED:		11/24/04	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

\* Will follow shortly